Showing results (391-400 of 514) with videos related to

Sort By:
Pageof 52
Blood|January 16, 2009
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLJianbiao Zhou, Chonglei Bi, Jasinghe V Janakakumara, et al.
Pediatric Hematology and Oncology|August 18, 2012
Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimenHeidrun Boztug, Cäcilia Karitnig-Weiß, Bernd Ausserer, et al.
International Journal of Cancer|April 3, 2020
Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II-Report from the German/Swiss SIOP-LGG 2004 cohortFabian Falkenstein, Marco Gessi, Daniela Kandels, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2017
Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrationsEhsan Bahrami, Maximilian Witzel, Tomas Racek, et al.
Journal of Medicinal Chemistry|June 19, 2008
7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitorsRobin R Frey, Michael L Curtin, Daniel H Albert, et al.
Molecular Cancer Therapeutics|May 5, 2017
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsLloyd T Lam, Xiaoyu Lin, Emily J Faivre, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2009
ORAI1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasiaChristie-Ann McCarl, Capucine Picard, Sara Khalil, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2018
Haploidentical Stem Cell Transplantation for Refractory/Relapsed NeuroblastomaToni Illhardt, Jacek Toporski, Tobias Feuchtinger, et al.
Investigational New Drugs|May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignanciesGuillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Pageof 52